NRF2, a Superstar of Ferroptosis
Open accessThe DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Abstract
Ferroptosis is an iron-dependent and lipid peroxidation-driven cell death cascade, occurring when there is an imbalance of redox homeostasis in the cell. Nuclear factor erythroid 2-related factor 2 (NFE2L2, also known as NRF2) is key for cellular antioxidant responses, which promotes downstream genes transcription by binding to their antioxidant response elements (AREs). Numerous studies suggest that NRF2 assumes an extremely important role in the regulation of ferroptosis, for its various functions in iron, lipid, and amino acid metabolism, and so on. Many pathological states are relevant to ferroptosis. Abnormal suppression of ferroptosis is found in many cases of cancer, promoting their progression and metastasis. While during tissue damages, ferroptosis is recurrently promoted, resulting in a large number of cell deaths and even dysfunctions of the corresponding organs. Therefore, targeting NRF2-related signaling pathways, to induce or inhibit ferroptosis, has become a great potential therapy for combating cancers, as well as preventing neurodegenerative and ischemic diseases. In this review, a brief overview of the research process of ferroptosis over the past decade will be presented. In particular, the mechanisms of ferroptosis and a focus on the regulation of ferroptosis by NRF2 will be discussed. Finally, the review will briefly list some clinical applications of targeting the NRF2 signaling pathway in the treatment of diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406
Regulation of Ferroptotic Cancer Cell Death by GPX4
Yang, W. S., SriRamaratnam, R., Welsch, M. E., Shimada, K., Skouta, R., Viswanathan, V. S., Cheah, J. H., Clemons, P. A., Shamji, A. F., Clish, C. B., et al. (2014) · Cell · doi:10.1016/j.cell.2013.12.010 · Cited by 7,713
Rahib, L., Smith, B. D., Aizenberg, R., Rosenzweig, A. B., Fleshman, J. M., & Matrisian, L. M. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0155 · Cited by 7,094
ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition
Doll, S., Proneth, B., Tyurina, Y. Y., Panzilius, E., Kobayashi, S., Ingold, I., Irmler, M., Beckers, J., Aichler, M., Walch, A., et al. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2239 · Cited by 4,293 · cited 1×
“In addition, studies have suggested that NRF2 indirectly participated in the regulation of lipid metabolism via PPAR γ (peroxisome proliferator-activated receptor-γ ) whose abundance was associated with cell sensitivity to ferroptosis [6].”
Itoh, K., Chiba, T., Takahashi, S., Ishii, T., Igarashi, K., Katoh, Y., Oyake, T., Hayashi, N., Satoh, K., Hatayama, I., et al. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.6943 · Cited by 3,999 · cited 1×
“…that NRF2 acted an essential part in the transcriptional induction of phase II detoxification genes carrying ARE (antioxidant response elements), after which roles of NRF2 in erythrocyte generation were marginalized, with studies shifting their focus from erythropoiesis to toxicology [10].”
Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice
Friedmann Angeli, J. P., Schneider, M., Proneth, B., Tyurina, Y. Y., Tyurin, V. A., Hammond, V. J., Herbach, N., Aichler, M., Walch, A., Eggenhofer, E., et al. (2014) · Nature Cell Biology · doi:10.1038/ncb3064 · Cited by 3,732 · cited 1×
“For example, intracellular depletion of GSH (glutathione), decreased activity of GPX4 (glutathione peroxidase 4), and accumulation of lipid peroxides are regarded as essential factors to promote ferroptosis [3,5].”
The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis
Bersuker, K., Hendricks, J. M., Li, Z., Magtanong, L., Ford, B., Tang, P. H., Roberts, M. A., Tong, B., Maimone, T. J., Zoncu, R., et al. (2019) · Nature · doi:10.1038/s41586-019-1705-2 · Cited by 3,703
FSP1 is a glutathione-independent ferroptosis suppressor
Doll, S., Freitas, F. P., Shah, R., Aldrovandi, M., da Silva, M. C., Ingold, I., Goya Grocin, A., Xavier da Silva, T. N., Panzilius, E., Scheel, C. H., et al. (2019) · Nature · doi:10.1038/s41586-019-1707-0 · Cited by 3,341
Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis
DeNicola, G. M., Karreth, F. A., Humpton, T. J., Gopinathan, A., Wei, C., Frese, K., Mangal, D., Yu, K. H., Yeo, C. J., Calhoun, E. S., et al. (2011) · Nature · doi:10.1038/nature10189 · Cited by 2,277
Role of Mitochondria in Ferroptosis
Gao, M., Yi, J., Zhu, J., Minikes, A. M., Monian, P., Thompson, C. B., & Jiang, X. (2019) · Molecular Cell · doi:10.1016/j.molcel.2018.10.042 · Cited by 2,120
Dixon, S. J., Patel, D. N., Welsch, M., Skouta, R., Lee, E. D., Hayano, M., Thomas, A. G., Gleason, C. E., Tatonetti, N. P., Slusher, B. S., et al. (2014) · eLife · doi:10.7554/elife.02523 · Cited by 2,088
Sun, X., Ou, Z., Chen, R., Niu, X., Chen, D., Kang, R., & Tang, D. (2016) · Hepatology · doi:10.1002/hep.28251 · Cited by 2,012 · cited 1×
“Some studies suggested that HO-1 promotes ferroptosis [34,35], while others reported opposing results that knockout or knockdown of HO-1 exacerbates ferroptosis [36–38].”
Yang, W. S., & Stockwell, B. R. (2008) · Chemistry & Biology · doi:10.1016/j.chembiol.2008.02.010 · Cited by 1,876 · cited 2×
“For example, intracellular depletion of GSH (glutathione), decreased activity of GPX4 (glutathione peroxidase 4), and accumulation of lipid peroxides are regarded as essential factors to promote ferroptosis [3,5].”
Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition
Hangauer, M. J., Viswanathan, V. S., Ryan, M. J., Bole, D., Eaton, J. K., Matov, A., Galeas, J., Dhruv, H. D., Berens, M. E., Schreiber, S. L., et al. (2017) · Nature · doi:10.1038/nature24297 · Cited by 1,799 · cited 1×
“It is worth mentioning that drug-resistant breast cancer cells often show stronger dependence on GPX4 and are more sensitive to GPX4 inhibitors [148].”
RAS–RAF–MEK-dependent oxidative cell death involving voltage-dependent anion channels
Yagoda, N., von Rechenberg, M., Zaganjor, E., Bauer, A. J., Yang, W. S., Fridman, D. J., Wolpaw, A. J., Smukste, I., Peltier, J. M., Boniface, J. J., et al. (2007) · Nature · doi:10.1038/nature05859 · Cited by 1,631
Moi, P., Chan, K., Asunis, I., Cao, A., & Kan, Y. W. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.21.9926 · Cited by 1,607 · cited 1×
“In 1994, Moi et al. [9] identified NRF2 as one of the DNA-binding proteins that could bind to AP-1/NF-E2 (activating protein-1/nuclear factor erythroid 2) in the locus control region of β -globin, assisting NF-E2 to mediate globin gene expression.”
Bender, A., Krishnan, K. J., Morris, C. M., Taylor, G. A., Reeve, A. K., Perry, R. H., Jaros, E., Hersheson, J. S., Betts, J., Klopstock, T., et al. (2006) · Nature Genetics · doi:10.1038/ng1769 · Cited by 1,570 · cited 1×
“Parkinson disease is characterized by mitochondrial dysfunction, iron accumulation, copper depletion, and GSH exhaustion in the brain, some of which are also the most important features of fer-roptosis [175–179].”
Role of GPX4 in ferroptosis and its pharmacological implication
Seibt, T. M., Proneth, B., & Conrad, M. (2019) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2018.09.014 · Cited by 1,520
Dolma, S., Lessnick, S. L., Hahn, W. C., & Stockwell, B. R. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00050-3 · Cited by 1,446
Nrf2 Redirects Glucose and Glutamine into Anabolic Pathways in Metabolic Reprogramming
Mitsuishi, Y., Taguchi, K., Kawatani, Y., Shibata, T., Nukiwa, T., Aburatani, H., Yamamoto, M., & Motohashi, H. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.05.016 · Cited by 1,395 · cited 2×
“NRF2 directly regulates the transcription of various PPP enzymes, such as G6PD (glucose-6-phosphate dehydrogenase) and other oxidative PPP enzymes [95], comprising reversible and irreversible reactions [96].”
Mechanisms of free radical oxidation of unsaturated lipids
Porter, N. A., Caldwell, S. E., & Mills, K. A. (1995) · Lipids · doi:10.1007/bf02536034 · Cited by 1,208 · cited 1×
“…of ferroptosis is Fenton reaction—Fe 2+ and O 2 (or ROS, reactive oxygen species) function as strong oxidants and peroxidize PL-PUFA (phospholipid with polyunsaturated fatty acyl tail) to PL-PUFA-OOH [15] in the catalysis of POR (cytochrome p450 oxidoreductases) [16] or LOXs (lipoxygenases) [17].”
Dexter, D. T., Wells, F. R., Lee, A. J., Agid, F., Agid, Y., Jenner, P., & Marsden, C. D. (1989) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1989.tb07264.x · Cited by 1,149
Ferrostatins Inhibit Oxidative Lipid Damage and Cell Death in Diverse Disease Models
Skouta, R., Dixon, S. J., Wang, J., Dunn, D. E., Orman, M., Shimada, K., Rosenberg, P. A., Lo, D. C., Weinberg, J. M., Linkermann, A., et al. (2014) · Journal of the American Chemical Society · doi:10.1021/ja411006a · Cited by 1,146 · cited 1×
“Biochemical and metabolomic analyses have demonstrated a notable decrease in GSH levels following erastin treatment [106].”
McMahon, M., Itoh, K., Yamamoto, M., & Hayes, J. D. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m300931200 · Cited by 1,141 · cited 1×
“The DLG and ETGE motifs on Neh2 domain bind with DC domain of Keap1 (kelch-like ECH-ssociated protein 1) homodimer [44,59], leading to the ubiquitination and degradation of NRF2 [60].”
Intercellular interaction dictates cancer cell ferroptosis via NF2–YAP signalling
Wu, J., Minikes, A. M., Gao, M., Bian, H., Li, Y., Stockwell, B. R., Chen, Z.-N., & Jiang, X. (2019) · Nature · doi:10.1038/s41586-019-1426-6 · Cited by 1,110 · cited 1×
“Thus, closure of Hippo pathway and increased YAPs can make cells more sensitive to ferroptosis [24].”
Dysfunctional KEAP1–NRF2 Interaction in Non-Small-Cell Lung Cancer
Singh, A., Misra, V., Thimmulappa, R. K., Lee, H., Ames, S., Hoque, M. O., Herman, J. G., Baylin, S. B., Sidransky, D., Gabrielson, E., et al. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030420 · Cited by 1,060 · cited 1×
“In the past decade, many studies have revealed that the activation of NRF2 in cancer cells promotes cancer progression [116–118] and metastasis [119], and confers cancer cells resistance to chemotherapy and radiotherapy [120,121].”
Global survey of cell death mechanisms reveals metabolic regulation of ferroptosis
Shimada, K., Skouta, R., Kaplan, A., Yang, W. S., Hayano, M., Dixon, S. J., Brown, L. M., Valenzuela, C. A., Wolpaw, A. J., & Stockwell, B. R. (2016) · Nature Chemical Biology · doi:10.1038/nchembio.2079 · Cited by 1,017
Fleming, M. D., Romano, M. A., Su, M. A., Garrick, L. M., Garrick, M. D., & Andrews, N. C. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.3.1148 · Cited by 936
Ohgami, R. S., Campagna, D. R., Greer, E. L., Antiochos, B., McDonald, A., Chen, J., Sharp, J. J., Fujiwara, Y., Barker, J. E., & Fleming, M. D. (2005) · Nature Genetics · doi:10.1038/ng1658 · Cited by 775 · cited 1×
“Fe3+ formed from intestinal absorption or erythrocyte degradation can be captured by Tf and imported into cells through TfR1 [25], after which it is reduced to Fe2+ by STEAP3 (six transmembrane epithelial antigen of the prostate 3) [26] and imported via DMT1 (ferrous ion membrane transport protein) [27].”
Tong, K. I., Katoh, Y., Kusunoki, H., Itoh, K., Tanaka, T., & Yamamoto, M. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.8.2887-2900.2006 · Cited by 759 · cited 3×
“As mentioned above, under normal circumstances, two molecules of Keap1 bind to the ETGE and DLG motifs on the Neh2 domain of NRF2 via its Kelch repeat domain [44,59].”
Rada, P., Rojo, A. I., Chowdhry, S., McMahon, M., Hayes, J. D., & Cuadrado, A. (2011) · Molecular and Cellular Biology · doi:10.1128/mcb.01204-10 · Cited by 759 · cited 1×
“Under the condition of homeostasis, NRF2 is phosphorylated by GSK-3 β , after which it can be recognized by β -TrCP, resulting in the ubiquitination of NRF2 by the β -TrCP-Cul1 E3 ubiquitin ligase complex and later degradation by proteasome [63,70,71].”
Sulfasalazine: A potent and specific inhibitor of nuclear factor kappa B
Wahl, C., Liptay, S., Adler, G., & Schmid, R. M. (1998) · Journal of Clinical Investigation · doi:10.1172/jci992 · Cited by 742
Structural basis for defects of Keap1 activity provoked by its point mutations in lung cancer
Padmanabhan, B., Tong, K. I., Ohta, T., Nakamura, Y., Scharlock, M., Ohtsuji, M., Kang, M.-I., Kobayashi, A., Yokoyama, S., & Yamamoto, M. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.01.013 · Cited by 735 · cited 1×
“In the past decade, many studies have revealed that the activation of NRF2 in cancer cells promotes cancer progression [116–118] and metastasis [119], and confers cancer cells resistance to chemotherapy and radiotherapy [120,121].”
Roh, J.-L., Kim, E. H., Jang, H., & Shin, D. (2017) · Redox Biology · doi:10.1016/j.redox.2016.12.010 · Cited by 662
Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis
Romero, R., Sayin, V. I., Davidson, S. M., Bauer, M. R., Singh, S. X., LeBoeuf, S. E., Karakousi, T. R., Ellis, D. C., Bhutkar, A., Sánchez-Rivera, F. J., et al. (2017) · Nature Medicine · doi:10.1038/nm.4407 · Cited by 652 · cited 1×
“As a result, less α -KG is generated from glutamate and TCA cycle is restricted, hence inhibiting generation of ROS by ETC (electron transport chain), the downstream process of TCA cycle [104].”
Gout, P., Buckley, A., Simms, C., & Bruchovsky, N. (2001) · Leukemia · doi:10.1038/sj.leu.2402238 · Cited by 640 · cited 2×
“Through disturbing cystine absorption, sulfasalazine mitigates the biosynthesis of GSH, resulting in ferroptosis [4] of some types of cancer cells in vivo and in vitro [130], such as lymphoma [129].”
Genetic or Pharmacological Iron Chelation Prevents MPTP-Induced Neurotoxicity In Vivo
Kaur, D., Yantiri, F., Rajagopalan, S., Kumar, J., Mo, J. Q., Boonplueang, R., Viswanath, V., Jacobs, R., Yang, L., Beal, M. F., et al. (2003) · Neuron · doi:10.1016/s0896-6273(03)00126-0 · Cited by 620
Tau deficiency induces parkinsonism with dementia by impairing APP-mediated iron export
Lei, P., Ayton, S., Finkelstein, D. I., Spoerri, L., Ciccotosto, G. D., Wright, D. K., Wong, B. X. W., Adlard, P. A., Cherny, R. A., Lam, L. Q., et al. (2012) · Nature Medicine · doi:10.1038/nm.2613 · Cited by 594 · cited 1×
“In animal models of neurodegenerative diseases as well as aging populations, varying degrees of elevation of iron content in the brain have been observed [168,169].”
Ferroptosis, but Not Necroptosis, Is Important in Nephrotoxic Folic Acid–Induced AKI
Martin-Sanchez, D., Ruiz-Andres, O., Poveda, J., Carrasco, S., Cannata-Ortiz, P., Sanchez-Niño, M. D., Ruiz Ortega, M., Egido, J., Linkermann, A., Ortiz, A., et al. (2017) · Journal of the American Society of Nephrology · doi:10.1681/asn.2015121376 · Cited by 564
Mitochondria as biosynthetic factories for cancer proliferation
Ahn, C. S., & Metallo, C. M. (2015) · Cancer & Metabolism · doi:10.1186/s40170-015-0128-2 · Cited by 399
Beneficial role of Nrf2 in regulating NADPH generation and consumption
Wu, K. C., Cui, J. Y., & Klaassen, C. D. (2011) · Toxicological Sciences · doi:10.1093/toxsci/kfr183 · Cited by 368
Anderson, G. J., & Vulpe, C. D. (2009) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-009-0051-1 · Cited by 317 · cited 1×
“The excess Fe 2+ can be oxidized and then exported by FPN1 (ferrous iron exporter ferro-portin 1) in the plasma membrane [29], utilized by mitochondria for heme synthesis, or oxidized and stored in ferritins by PCBP1 (poly-(rC)-binding protein 1) [30].”
Rushworth, S. A., Zaitseva, L., Murray, M. Y., Shah, N. M., Bowles, K. M., & MacEwan, D. J. (2012) · Blood · doi:10.1182/blood-2012-04-422121 · Cited by 290
System xc− and Thioredoxin Reductase 1 Cooperatively Rescue Glutathione Deficiency
Mandal, P. K., Seiler, A., Perisic, T., Kölle, P., Banjac Canak, A., Förster, H., Weiss, N., Kremmer, E., Lieberman, M. W., Bannai, S., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.121327 · Cited by 269 · cited 1×
“NADPH is not only crucial for the synthesis of fatty acids (such as PUFAs), cholesterol, and nucleotides [97], but also important in antioxidation axes such as GPX4, FSP1, and DHFR [19,98,99].”
Ceruloplasmin dysfunction and therapeutic potential for Parkinson disease
Ayton, S., Lei, P., Duce, J. A., Wong, B. X. W., Sedjahtera, A., Adlard, P. A., Bush, A. I., & Finkelstein, D. I. (2013) · Annals of Neurology · doi:10.1002/ana.23817 · Cited by 264 · cited 1×
“Parkinson disease is characterized by mitochondrial dysfunction, iron accumulation, copper depletion, and GSH exhaustion in the brain, some of which are also the most important features of fer-roptosis [175–179].”
Inhibition of selenoprotein synthesis by selenocysteine tRNA[Ser]Sec lacking isopentenyladenosine
Warner, G. J., Berry, M. J., Moustafa, M. E., Carlson, B. A., Hatfield, D. L., & Faust, J. R. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m001280200 · Cited by 207 · cited 1×
“Since GPX4 is a selenoprotein, its biosynthesis relies on the co-translational incorporation of Sec (selenocysteine) [ for the maturation of selenocysteine tRNA for GPX4 [52].”
Huang, K., Gao, X., & Wei, W. (2017) · Experimental Cell Research · doi:10.1016/j.yexcr.2017.09.042 · Cited by 155
Kasarskis, E. J., Tandon, L., Lovell, M. A., & Ehmann, W. D. (1995) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(95)00037-3 · Cited by 145
Guan, J., Lo, M., Dockery, P., Mahon, S., Karp, C. M., Buckley, A. R., Lam, S., Gout, P. W., & Wang, Y.-Z. (2009) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-008-0894-4 · Cited by 134
Metadata
- Authors
- Yan, R., Lin, B., Jin, W., Tang, L., Hu, S., & Cai, R.
- Venue
- Antioxidants
- Publisher
- MDPI AG
- Published
- 2023-09-08
- Volume
- 12
- Issue
- 9
- Pages
- 1739
- ISSN
- 2076-3921 (ISSN-L)
- OpenAlex
- W4386559765
- Cited by
- 252
- References
- 51
- FWCI
- 40.03
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.